Open Clinical Investigation to Evaluate the Effectiveness and Safety of a Topical Medical Device.
Study Details
Study Description
Brief Summary
The primary endpoint is the change of the itching score after 3 days of the product use in comparison to the basal value.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: Poxclin Coolmousse A cooling mousse for application to the skin supplied in a 100 mL plastic bottle with a pump (a foamer) |
Device: Poxclin Coolmousse
cooling mousse for application in the skin
|
Outcome Measures
Primary Outcome Measures
- The efficacy of PoxClin® CoolMousse in relieving itching associated with chickenpox (using 5-point scale,"none (0)" to "severe (4)" ) will be evaluated after 3 days. [3 days]
Children should be diagnosed with chickenpox.
Secondary Outcome Measures
- The efficacy of the PoxClin® CoolMousse in relieving itch during chickenpox (using 5 point scale, "none (0)" to "severe (4)"): itching) will be evaluated after 7 days. [7 days]
Children should be diagnosed with chickenpox.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Female and/or male
-
Aged between 12 months to 11 years
-
phototype: I to IV
-
Subject or parent(s)/legal representative(s) must be registered with health social security or health social insurance.
-
Parent(s)/legal representative(s) having signed their written Informed Consent form (ICF) for their children's participation in the study
-
Subject and / or parent(s)/legal representative(s) able to understand the language used in the investigation centre and the information given
-
Subject or parent(s)/legal representative(s) able to comply with the protocol, follow protocol's constraints and specific requirements and able to follow the medical recommendation regarding the pathology and its requirements (treatment, social eviction etc)
-
Subjects presenting non severe and non complicated chicken pox
Exclusion Criteria:
-
Subject or parent(s)/legal representative(s) who is (are) unable to understand the information (for linguistic or psychiatric reasons) and to give his/her (their) consent to his/ her (their child) participation
-
Subject taking part or planning to participate in another clinical trial during the study in the same or another investigation centre
-
Subject or parent(s)/legal representative(s) deprived of freedom by administrative or legal decision or under guardianship
-
Subject or parent(s)/legal representative(s) admitted in a sanitary or social facility
-
Subjects planning a hospitalization during the study
-
Severe or complicated chicken pox (surinfection, profuse eruption, pneumonia, etc)
-
Having an acute, chronic, or progressive disease or dermatological condition liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements
-
Having personal medical history liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements
-
Being under any treatment for a severe or complicated chicken pox considered by the Investigator liable to interfere with the study data or incompatible with the study requirements (antiviral (Herviran) or antibiotics...)
-
Having taken any previous treatment considered by the Investigator liable to interfere with the study data or incompatible with the study requirements
-
Systemic antibiotics within 1 week before the inclusion or required during the study
-
Systemic immunosuppressive treatment within 6 months before the inclusion or required during the study
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Ewa Karamon, private practice | Malbork | Poland |
Sponsors and Collaborators
- Karo Pharma AB
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 22E3464/ PXC_001